Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2017 August;58(4) > The Journal of Cardiovascular Surgery 2017 August;58(4):501-7

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

REVIEW  RECENT DEVELOPMENTS IN THE MANAGEMENT OF IN-STENT RESTENOSISFREEfree


The Journal of Cardiovascular Surgery 2017 August;58(4):501-7

DOI: 10.23736/S0021-9509.17.09963-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of drug-coated balloons in in-stent restenosis

Martin ANDRASSY 1 , Sultan CELIK 1, Joachim ANDRASSY 2, Michael K. LICHTENBERG 3, Marianne BRODMANN 4

1 Department of Cardiology, Angiology, Diabetology, Fürst-Stirum-Klinik, Bruchsal, Germany; 2 Department of Surgery, University Hospital Munich, Munich, Germany; 3 Vascular Centre Arnsberg Clinic, Arnsberg, Germany; 4 Department of Angiology, University of Graz, Graz, Austria


FULL TEXT  


Despite a constantly expanding spectrum of therapeutic options for lower limb artery disease, there is not yet a well-defined consensus on the specific type of endovascular treatment that is best suited. Clinical data on patients with femoropopliteal disease treated with drug-coated balloons have not been elaborated sufficiently, especially in the case of in-stent restenosis. For this review a systematic research of the medical databases (Pubmed) has been conducted. Keywords such as “drug-coated balloons” (DCB), “drug-eluting balloons,” “in-stent restenosis”, “de novo stenosis”, “angioplasty”, “superficial femoral artery,” “popliteal artery,” “above the knee,” “below the knee,” “peripheral artery disease” (PAD) have been used. Furthermore, data from reviews, original contributions regarding randomized controlled studies, observational studies, registries and single center experiences have been included. Many trials have shown superiority for DCB- over percutaneous transluminal angioplasty-treatment alone in TASC IIA and TASC IIB femoropopliteal lesions. However, the currently available DCB systems are different in terms of efficacy and long-term outcomes depending on their mechanical and pharmacological features. Moreover, angiographic characteristics of femoropopliteal lesions classified by Tosaka seem to influence subsequent outcomes of DCB treatment. Lastly, there is still lack of reliable prospective long-term data regarding DCB technology.


KEY WORDS: Angioplasty, balloon - Coronary restenosis - Stents

inizio pagina

Publication History

Issue published online: June 5, 2017
Article first published online: March 28, 2017

Per citare questo articolo

Andrassy M, Celik S, Andrassy J, Lichtenberg MK, Brodmann M. The role of drug-coated balloons in in-stent restenosis. J Cardiovasc Surg 2017;58:501-7. DOI: 10.23736/S0021-9509.17.09963-3

Corresponding author e-mail

martin.andrassy@kliniken-lk.de